Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

Collaborative Care Essential for Diagnosis & Care of Neurosarcoidosis

Ruth Jessen Hickman, MD  |  November 26, 2024

At a ACR Convergence 2024 session, experts discussed key characteristics, diagnostic challenges & treatment considerations for neurosarcoidosis.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024Sarcoidosis

ADOBE STOCK | Feodora

The Great Pediatric Debate 2024: Cessation or Continuation of Biologics in sJIA Lung Disease?

Ruth Jessen Hickman, MD  |  November 23, 2024

Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…

Filed under:ACR ConvergenceConditionsPediatric Conditions Tagged with:ACR Convergence 2024sJIAsJIA-associated lung disease

AC&R Study Summary: Standardizing Treatment for Moderately Severe JDM

By Matthew A. Sherman, MD, MHSc, & Stacey E. Tarvin, MD, MS  |  November 10, 2024

Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesMyositisResearch Rheum Tagged with:juvenile dermatomyositisReading Rheum

What’s New in Large Vessel Vasculitis

Philip Seo, MD, MHS  |  August 7, 2024

The large vessel vasculitides were a major focus of the 21st International Vasculitis Workshop held in Barcelona in April. The biennial conference brings together specialists from multiple disciplines, including rheumatology, nephrology and immunology, to discuss cutting-edge vasculitis research. This article reviews important points regarding the pathogenesis, diagnosis and management of both giant cell arteritis and…

Filed under:ConditionsGuidanceResearch RheumVasculitis Tagged with:diverticulitisgastrointestinal perforationGiant Cell Arteritisgiant cell arteritis (GCA)interleukin-17A inhibitorlarge-vessel vasculitisTakayasu arteritis (TAK)Takayasu’s Arteritistocilizumab

What’s New in Polymyalgia Rheumatica?

Jason Liebowitz, MD, FACR  |  July 31, 2024

Should all patients with polymyalgia rheumatica (PMR) have a vascular ultrasound assessment? What treatments are the safest and most efficacious for patients with PMR? Frank Buttgereit, MD, answered these questions and highlighted the latest research on PMR in this session at EULAR 2024.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPain Syndromes Tagged with:EULAR 2024GCAgiant cell arteritis (GCA)PMRPolymyalgia Rheumatica

Editor's Pick

The ACR and CHEST Release 2 New ILD Guidelines

Ruth Jessen Hickman, MD  |  July 9, 2024

Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOther Rheumatic ConditionsRheumatoid ArthritisSjögren’s DiseaseSystemic Sclerosis Tagged with:Editor's PickILDInterstitial Lung Diseaseinterstitial lung disease (ILD)Sjogren's

CAR-T Cell Therapy in Autoimmune Disease: The Next Frontier

Jason Liebowitz, MD, FACR  |  July 2, 2024

Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.

Filed under:Biologics/DMARDsConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:CAR-T cell therapychimeric antigen receptor T (CAR-T) cellsEULAR 2024ImmunologyResearchSLE Resource Centersystemic lupus erythematosus (SLE)

Telehealth Triage Study Seeks to Close Gaps in Care

Gretchen Henkel  |  May 5, 2024

Reducing the time to diagnosis and initiation of appropriate treatment is paramount to intercept inflammatory damage in patients at the onset of rheumatic disease. But those targets can be delayed by provider shortages and other barriers to care. Since last June, Remission Medical, a virtual rheumatology clinic, has been partnering with Mayo Clinic to find…

Filed under:Practice SupportTechnology Tagged with:DiagnosisMayo Clinictelehealthtriage

Case Report: Persistent Pruritic Plaques in Adult-Onset Still’s Disease

Kubra Bugdayli, MD, Ahmed Eldaboush, MD, Sanjana Aggarwal, MBBS, & Bonnie Bermas, MD  |  May 5, 2024

Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder characterized by persistent fever at regular intervals, arthralgias or arthritis, rash, sore throat and neutrophilic leukocytosis.1,2 Significant elevation in ferritin levels is characteristic and tends to correlate with disease activity. Additional clinical features may include myalgias, lymphadenopathy, hepatosplenomegaly, serositis, myocarditis, abnormal liver function tests and development…

Filed under:ConditionsMyositisOther Rheumatic Conditions Tagged with:adult onset Still's diseasecase reportdermatomyositisdermatomyositis (DM)Fellows Forummalignancymimics

Polymyalgia Rheumatica: New Tricks for an Old Disease

Desh Nepal, MD, Sebastian E. Sattui, MD, MS, & Michael Putman, MD, MS  |  January 29, 2024

Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

Filed under:ACR ConvergenceConditionsMeeting ReportsSoft Tissue Pain Tagged with:ACR Convergence 2022Disease-modifying antirheumatic drugs (DMARDs)GlucocorticoidsIL-6IL-6 inhibitorsimagingPMR FocusRheumPolymyalgia Rheumatica

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences